TCT联合高危型HPV检测诊断宫颈癌的研究进展
|
摘要
液基薄层细胞学检测(TCT)取材及制片均比较简单,能够进行系统程序化的处理,对宫颈上皮内异样细胞的检出率明显高于传统的巴氏涂片法,同时能够弥补传统涂片的不足与缺陷,提高标本的可信度,降低假阴性率。人乳头瘤病毒(HPV)在宫颈癌及癌前病变发生、发展中起到关键性作用。高危型HPV与宫颈癌的发生密切相关,因此高危型HPV DNA检测是筛查宫颈癌及癌前病变最直接、有效的方法,能够减低TCT检测的假阴性率。并且高危HPV检测的阳性率随着TCT检测分级的增高而上升,对TCT检测中的不能明确诊断意义的不典型鳞状上皮细胞(ASCUS)及以上的病变行高危HPV检测能够分流检测结果,更精准地筛选高风险人群,提高早期筛查的针对性。TCT联合高危型HPV检测能够提高宫颈癌的筛查效率,提高检查准确性和特异性。
Liquid thin-layer cytology test(TCT) materials and production are relatively simple, ability of system processing, stylized for detection of cervical intraepithelial strange cells was obviously higher than that of the traditional pap smear method, can make up for the inadequacy of traditional smear and defects at the same time, improve the credibility of specimens, reduce the false negative rate. Human papilloma virus(HPV) plays a key role in the occurrence and development of cervical cancer and precancerous lesions,high-risk type HPV is closely related to the occurrence of cervical cancer, so high-risk HPV DNA detection is the most direct and effective method to screen cervical cancer and precancerous lesions that can reduce the false negative rate of TCT detection. The positive rate of high-risk HPV test increased with the increase of TCT grade. High-risk HPV detection can shunt the detection results of atypical squamous epithelial cells(ASCUS) and lesions above which TCT can not be clearly diagnosed, and improve the pertinence of early screening. TCT combined with high-risk HPV test can improve screening efficiency and improve accuracy and specificity of cervical cancer.
Liquid thin-layer cytology test(TCT) materials and production are relatively simple, ability of system processing, stylized for detection of cervical intraepithelial strange cells was obviously higher than that of the traditional pap smear method, can make up for the inadequacy of traditional smear and defects at the same time, improve the credibility of specimens, reduce the false negative rate. Human papilloma virus(HPV) plays a key role in the occurrence and development of cervical cancer and precancerous lesions,high-risk type HPV is closely related to the occurrence of cervical cancer, so high-risk HPV DNA detection is the most direct and effective method to screen cervical cancer and precancerous lesions that can reduce the false negative rate of TCT detection. The positive rate of high-risk HPV test increased with the increase of TCT grade. High-risk HPV detection can shunt the detection results of atypical squamous epithelial cells(ASCUS) and lesions above which TCT can not be clearly diagnosed, and improve the pertinence of early screening. TCT combined with high-risk HPV test can improve screening efficiency and improve accuracy and specificity of cervical cancer.
引文
[1]Río-Ospina LD,León SD,Camargo M,e t al.The DNA load of six high-risk human papillomavirus types and its association with cervical lesions[J].BMC Cancer,2015,15(1):1126-1127.
[2]吴晓蓉,代逃芳.TCT、HPV检查联合阴道镜对宫颈癌筛查的临床价值研究[J].中外医学研究,2017,15(10):16-17.
[3]刘桃柳.TCT+HPV分型联合检测早期宫颈病变的临床观察[J].中外医学研究,2017,15(2):59-60.
[4]高华玲,尹德娥,杜杰,等.TCT和HR-HPV-DNA检测在宫颈癌和癌前病变筛查中的临床价值[J].标记免疫分析与临床,2017,24(10):1115-1118.
[5]刘国艳.TCT及HPV联合阴道镜检查在宫颈癌筛查中的应用[J].中国医药指南,2017(34):46-47.
[6]侯雪梅.高危型HPV检测联合TCT用于宫颈癌筛查及意义[J].临床医学,2017,37(4):94-95.
[7]潘秦镜,李凌,乔友林,等.液基细胞学筛查宫颈癌的研究[J].中华肿瘤杂志,2001,23(4):309-312.
[8]张建新,张长淮,周艳秋,等.15393例宫颈液基细胞学与组织病理学的对照分析[J].中华病理学杂志,2007,36(7),485-488.
[9]孙蕾蕾,李绍条,林兴园.高危型HPV-DNA联合液基细胞学检测对宫颈癌筛查的价值[J].中国生化药物杂志,2017,37(1):283-285.
[10]Nabi G.Knowledge of Saudi female university students regarding cervical cancer end acceptance of the human papilloma virus[J].Saudi Med J,2015,36(2):254-255.
[11]姜仙姣,李奕平,牟虹.TCT联合HPV分型检测在宫颈癌前病变筛查中的应用分析[J].浙江临床医学,2017,19(3):481-482.
[12]王琳.高危型HPV检测及TCT检查在宫颈癌筛查和诊断中的应用[J].中国医药导刊,2017,19(2):128-129.
[13]王美英,李芬,杜希林,等.高危型HPVDNA联合TCT检测在宫颈癌初筛中的应用价值[J].国际检验医学杂志,2017,38(5):620-621.
[14]袁俊杰,张宜权,赵荣平.高危型人乳头瘤病毒与薄层细胞学联合检测在宫颈病变中的相关性研究[J].检验医学与临床,2017,14(A01):85-87.
[15]宋亚锋.高危型HPV联合TCT检查在宫颈癌筛查中的应用价值研究[J].临床医学,2017,37(7):89-91.
[16]潘敏,邓再兴,桂启芳.液基细胞学联合高危型人乳头状瘤病毒-DNA检测在早期宫颈癌及癌前病变诊断中的临床价值[J].中国卫生检验杂志,2017(15):2208-2210.
[17]张丽鸯,吕杰强.液基薄层细胞学联合高危型人乳头瘤病毒检测诊断宫颈癌及癌前病变的价值[J].中国妇幼保健,2017,32(15):3670-3672.
[18]刘金舫,关晓梅,陈素芳,等.HC2-HPV-DNA联合TCT早期诊断宫颈癌的价值分析[J].癌症进展,2017,15(8):917-919.
[19]Monsonego J,Cox JT,Behrens C,et a1.Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S.screening population:data from the A-THENA trial[J].Gynecol Oncol,2015,137(1):47-54.
[20]汪晓菁.液基细胞学检查联合人乳头瘤病毒检测诊断宫颈癌前病变的临床价值[J].中国妇幼保健,2017(21):5443-5446.
[2]吴晓蓉,代逃芳.TCT、HPV检查联合阴道镜对宫颈癌筛查的临床价值研究[J].中外医学研究,2017,15(10):16-17.
[3]刘桃柳.TCT+HPV分型联合检测早期宫颈病变的临床观察[J].中外医学研究,2017,15(2):59-60.
[4]高华玲,尹德娥,杜杰,等.TCT和HR-HPV-DNA检测在宫颈癌和癌前病变筛查中的临床价值[J].标记免疫分析与临床,2017,24(10):1115-1118.
[5]刘国艳.TCT及HPV联合阴道镜检查在宫颈癌筛查中的应用[J].中国医药指南,2017(34):46-47.
[6]侯雪梅.高危型HPV检测联合TCT用于宫颈癌筛查及意义[J].临床医学,2017,37(4):94-95.
[7]潘秦镜,李凌,乔友林,等.液基细胞学筛查宫颈癌的研究[J].中华肿瘤杂志,2001,23(4):309-312.
[8]张建新,张长淮,周艳秋,等.15393例宫颈液基细胞学与组织病理学的对照分析[J].中华病理学杂志,2007,36(7),485-488.
[9]孙蕾蕾,李绍条,林兴园.高危型HPV-DNA联合液基细胞学检测对宫颈癌筛查的价值[J].中国生化药物杂志,2017,37(1):283-285.
[10]Nabi G.Knowledge of Saudi female university students regarding cervical cancer end acceptance of the human papilloma virus[J].Saudi Med J,2015,36(2):254-255.
[11]姜仙姣,李奕平,牟虹.TCT联合HPV分型检测在宫颈癌前病变筛查中的应用分析[J].浙江临床医学,2017,19(3):481-482.
[12]王琳.高危型HPV检测及TCT检查在宫颈癌筛查和诊断中的应用[J].中国医药导刊,2017,19(2):128-129.
[13]王美英,李芬,杜希林,等.高危型HPVDNA联合TCT检测在宫颈癌初筛中的应用价值[J].国际检验医学杂志,2017,38(5):620-621.
[14]袁俊杰,张宜权,赵荣平.高危型人乳头瘤病毒与薄层细胞学联合检测在宫颈病变中的相关性研究[J].检验医学与临床,2017,14(A01):85-87.
[15]宋亚锋.高危型HPV联合TCT检查在宫颈癌筛查中的应用价值研究[J].临床医学,2017,37(7):89-91.
[16]潘敏,邓再兴,桂启芳.液基细胞学联合高危型人乳头状瘤病毒-DNA检测在早期宫颈癌及癌前病变诊断中的临床价值[J].中国卫生检验杂志,2017(15):2208-2210.
[17]张丽鸯,吕杰强.液基薄层细胞学联合高危型人乳头瘤病毒检测诊断宫颈癌及癌前病变的价值[J].中国妇幼保健,2017,32(15):3670-3672.
[18]刘金舫,关晓梅,陈素芳,等.HC2-HPV-DNA联合TCT早期诊断宫颈癌的价值分析[J].癌症进展,2017,15(8):917-919.
[19]Monsonego J,Cox JT,Behrens C,et a1.Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S.screening population:data from the A-THENA trial[J].Gynecol Oncol,2015,137(1):47-54.
[20]汪晓菁.液基细胞学检查联合人乳头瘤病毒检测诊断宫颈癌前病变的临床价值[J].中国妇幼保健,2017(21):5443-5446.